Market Outlook

By 2035, the U.S. Digital Diabetes Care Devices Market is projected to reach approximately USD 31.67 billion, expanding at a CAGR of 10.34% during the forecast period 2026–2035. The market is estimated at USD 11.84 billion in 2025, with historical analysis covering 2021–2024. All values in this report are expressed in USD billions.

The U.S. digital diabetes care devices industry is moving from a glucose-measurement market toward an integrated, continuous and increasingly automated diabetes-management ecosystem. Continuous glucose monitoring systems, connected insulin pumps, automated insulin delivery platforms, smart blood glucose meters, digitally enabled insulin pens, implantable glucose sensors and interoperable monitoring technologies are progressively replacing episodic testing and manually intensive treatment workflows.

The addressable clinical population remains exceptionally large. More than 40 million people in the United States have diagnosed or undiagnosed diabetes, while more than 115 million adults have prediabetes. Approximately 29 million people have diagnosed diabetes, creating a substantial recurring device opportunity even before considering broader adoption among people with prediabetes, non-insulin-treated type 2 diabetes and consumers seeking metabolic-health information. The growing diagnosed population is important, but the more significant commercial shift is the widening proportion of patients who can realistically enter connected monitoring workflows.

The historical market expanded from an estimated USD 6.78 billion in 2021 to USD 10.36 billion in 2024, representing strong double-digit annualized growth. The market reached approximately USD 11.84 billion in 2025, supported primarily by rapid CGM penetration, recurring sensor revenue, wider automated insulin delivery adoption, improved Medicare access, pharmacy-channel availability and the launch of increasingly consumer-friendly glucose-monitoring technologies.

The growth profile is structurally attractive because much of device revenue is recurring rather than purely capital based. CGM sensors require replacement, insulin delivery systems generate continuing consumable demand, infusion sets and pods create recurring revenue, and digital ecosystems improve patient retention by linking hardware to mobile applications, clinicians, caregivers and cloud-based analytics.

The forecast assumes progressive expansion beyond the traditional type 1 diabetes technology population. By 2035, the largest incremental opportunity is expected to emerge from insulin-treated type 2 diabetes, followed by selected non-insulin-treated type 2 diabetes users. OTC glucose monitoring, longer-wear sensors, simplified automated insulin delivery systems, pharmacy-based distribution and broader reimbursement can substantially increase the number of Americans interacting with digital diabetes devices.

The market model includes prescription and OTC CGM systems, connected and automated insulin delivery devices, digitally connected blood glucose meters, smart insulin pens and pen attachments, implantable glucose sensors and clinically oriented digital monitoring hardware. Pure software applications without an associated medical-device or diabetes-monitoring hardware workflow are excluded to avoid overstating the device market.

 

Introduction

According to the U.S. Digital Diabetes Care Devices Market Report, digital diabetes technology is becoming one of the most strategically important areas of U.S. chronic disease management. The category sits at the intersection of medical devices, wearable sensing, connected drug delivery, mobile health, artificial intelligence, remote patient monitoring and personalized chronic care.

The market is being shaped by a fundamental change in how glucose information is generated and used. Traditional blood glucose meters provide isolated measurements. Newer digital systems create continuously updated datasets that can identify glucose direction, variability, time in range, nocturnal events and responses to food, activity and medication. When connected to insulin delivery systems, these data can also influence or automatically modify insulin administration.

This transition changes the economic value of a diabetes device. The device is no longer evaluated only by measurement accuracy or hardware price. Patients increasingly consider sensor wear duration, comfort, smartphone compatibility, alert reliability and application usability. Endocrinologists evaluate data visualization, time-in-range interpretation and integration with clinical workflows. Health systems consider whether devices can reduce severe hypoglycemia, acute utilization and clinician workload. Payers assess total cost of care, adherence, patient eligibility and utilization management.

The large type 2 diabetes population represents the central long-term commercial opportunity. Historically, sophisticated diabetes devices were concentrated among people with type 1 diabetes and intensive insulin therapy. That boundary is becoming less rigid as CGM evidence expands, reimbursement improves and automated insulin delivery receives broader indications. OTC monitoring is simultaneously creating a direct-access pathway for people who previously might not have obtained a prescribed glucose sensor.

Demographics strengthen this opportunity. More than 31 million Americans aged 65 years and older have prediabetes, while diabetes prevalence increases considerably in older age groups. This makes Medicare policy particularly influential for digital diabetes technology adoption. At the same time, younger consumers are increasingly comfortable managing health through smartphones and wearables, reducing behavioral barriers to sensor-based monitoring.

The U.S. is therefore developing into a multi-channel diabetes device market spanning endocrinology practices, primary care, hospital systems, pharmacies, durable medical equipment suppliers, virtual care organizations, employers and direct-to-consumer platforms. Manufacturers that can operate effectively across these channels are likely to achieve stronger growth than companies dependent on one traditional prescription pathway.

 

Key Market Drivers: What’s Fueling the U.S. Digital Diabetes Care Devices Market Boom?

The first structural driver is the scale of the U.S. diabetes population. Approximately 40.1 million Americans have diabetes, equivalent to roughly 12% of the population, while about 115.2 million adults have prediabetes. More than one-quarter of adults with diabetes remain undiagnosed. This creates both a large established treatment market and a substantial pool of people who could enter earlier digital monitoring pathways as screening and consumer access improve.

The second driver is the widening clinical role of continuous glucose monitoring. CGM is progressively moving from a premium technology for intensive insulin users toward a standard diabetes-management infrastructure. Continuous readings enable clinicians and patients to evaluate glucose patterns rather than rely only on individual fingerstick measurements. This creates value in insulin titration, hypoglycemia detection, behavioral feedback and medication assessment.

Recurring sensor economics also make CGM commercially important. Unlike traditional glucose meters, where the meter itself is inexpensive and revenue is driven through test strips, modern CGM creates predictable replacement cycles through wearable sensors. As the installed patient base grows, recurring consumable revenue compounds even when pricing becomes more competitive.

The third driver is reimbursement expansion. Medicare coverage criteria have evolved materially, reducing historical restrictions tied to intensive multi-injection insulin regimens. Current coverage pathways include qualifying insulin-treated patients and selected beneficiaries with problematic hypoglycemia. This is particularly significant because older adults represent a large proportion of the U.S. diabetes population and often have elevated hypoglycemia risk, comorbidities and medication complexity.

Commercial payers increasingly influence adoption through formulary placement, pharmacy benefits, DME contracts and preferred-device arrangements. Manufacturers therefore compete not only for physician preference but also for payer access. A device with strong clinical performance but limited formulary placement can face slower adoption than a competitively positioned system with broad pharmacy availability.

The fourth driver is automated insulin delivery. AID systems combine CGM data, algorithm-based dosing and insulin-pump technology to automatically adjust insulin delivery. These systems reduce some of the daily calculation burden associated with intensive diabetes management and create a much more integrated device value proposition.

The expansion of automated insulin dosing into type 2 diabetes is strategically important. The U.S. type 2 diabetes population is many times larger than the type 1 population. Even modest adoption among insulin-treated type 2 patients can materially increase the addressable market for pumps, wearable pods, sensors and algorithm-enabled controllers.

The fifth driver is OTC CGM access. The first U.S. OTC CGM clearances fundamentally changed the distribution model by allowing eligible consumers to obtain glucose sensors without the traditional physician-prescription journey. This creates an adjacent market among non-insulin-treated adults with type 2 diabetes and people using glucose information to understand metabolic response.

OTC availability is likely to encourage new pricing models, subscription programs, retail pharmacy partnerships and consumer-focused product design. The economics of this segment will differ from prescription CGM because reimbursement may be less central, but the potential population is substantially larger.

The sixth driver is interoperability. Diabetes devices increasingly operate as components of connected ecosystems rather than standalone hardware. CGMs can connect with insulin pumps, dosing algorithms, smartphone applications and cloud-based clinical platforms. Interoperable architecture allows patients to combine compatible technologies and reduces the dependence of the entire care workflow on one physical device.

The seventh driver is the economic burden of diabetes. Diabetes accounts for hundreds of billions of dollars in U.S. healthcare and productivity costs. The economic burden strengthens payer and health-system interest in technologies that can improve glycemic management, identify deterioration earlier and potentially reduce costly complications.

The eighth driver is patient convenience. Reduced fingersticks, smaller sensors, simpler insertion, smartphone display, longer wear periods, fewer calibrations and automated data sharing reduce friction. Convenience is commercially significant because chronic devices must be used repeatedly over years. Technologies that create excessive alarm burden, adhesive problems, complicated setup or difficult refill processes face higher discontinuation risk.

A moderating factor is the increasing use of GLP-1 therapies. More than one-quarter of U.S. adults with diagnosed diabetes reported GLP-1 injectable use in 2024. These medicines can change insulin requirements and glucose-management patterns for certain patients. However, they can also increase the value of digital monitoring by allowing patients and clinicians to observe treatment response, potentially broadening glucose sensing beyond conventional intensive insulin users.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in digital diabetes care is increasingly concentrated around automation, wear duration, interoperability, miniaturization, access and actionable data. Manufacturers are no longer competing only to deliver an accurate glucose number. The competitive objective is to reduce the number of decisions the patient must make while increasing the clinical usefulness of every data point generated.

Longer-wear sensors are a major innovation direction. Extending sensor life can lower insertion frequency, improve convenience and potentially improve lifetime device economics. Implantable CGM represents the most advanced expression of this trend, offering substantially longer wear than conventional disposable transcutaneous sensors.

CGM miniaturization remains equally important. Smaller sensors can improve discretion and patient comfort, while simplified applicators reduce training requirements. Consumer expectations increasingly resemble expectations for electronic wearables: devices must work reliably but also fit naturally into everyday life.

Automated insulin delivery is the highest-value innovation layer. Modern systems combine an interoperable CGM, algorithmic controller and insulin pump or wearable pod. The software continuously interprets glucose trends and adjusts insulin delivery according to system parameters. Competition is shifting toward ease of initialization, meal-announcement requirements, algorithm performance, sensor compatibility, pump form factor and time spent in automated mode.

Artificial intelligence and predictive analytics are also becoming more important. The near-term commercial opportunity is not autonomous diagnosis but workflow prioritization. Digital systems can help identify persistent hyperglycemia, recurring nocturnal hypoglycemia, glycemic variability or other patterns that warrant clinical review. In high-volume diabetes practices, this could reduce the amount of raw data clinicians need to examine manually.

Manufacturers are also designing products for broader patient populations. The development of OTC CGMs, non-intensive glucose-monitoring systems and simpler wearable insulin-delivery options shows that innovation is moving beyond highly technology-literate type 1 diabetes users. Future systems will increasingly need to accommodate older adults, caregivers, primary-care physicians and patients who have never previously used a wearable medical device.

Cybersecurity and smartphone reliability are becoming core product-development considerations. As safety alerts and therapy information migrate to mobile devices, software updates, Bluetooth connectivity, operating-system compatibility, notification permissions and handset settings can influence clinical safety. Device companies must therefore manage technology dependencies that did not exist in conventional standalone glucose meters.

Clinical evidence remains central. Premium adoption will increasingly depend on demonstrating improvements in time in range, hypoglycemia exposure, A1C, treatment burden, adherence, quality of life and healthcare utilization. Companies able to combine strong device engineering with clinical evidence and payer-ready health-economic data will be positioned to defend value despite increasing price competition.

 

Segmentation Insights

The U.S. Digital Diabetes Care Devices Market is segmented on the basis of product type, diabetes type, technology type, end user and region.

 

By Product Type

Continuous Glucose Monitoring Systems

Continuous glucose monitoring is the largest product category and accounted for an estimated 45.6% of the U.S. market in 2025, equivalent to approximately USD 5.40 billion. The category includes real-time CGM, intermittently scanned systems, implantable CGM and newer OTC glucose-monitoring platforms.

CGM is expected to remain the market’s primary growth engine because of recurring sensor replacement, improving reimbursement and expanding eligibility. The competitive focus is shifting toward wear duration, sensor size, application quality, accuracy across glucose ranges, integration with insulin-delivery systems and ease of pharmacy fulfillment.

The category is also expanding beyond traditional insulin-intensive patients. OTC products create a new commercial layer in which manufacturers compete for consumers who may not previously have participated in the prescription diabetes-device market. This could make retail pricing, customer acquisition, subscription retention and consumer education increasingly important competitive capabilities.

Connected and Automated Insulin Delivery Devices

Connected insulin pumps, tubeless pumps and automated insulin delivery systems represented approximately 31.2% of 2025 market value, or around USD 3.69 billion. The category combines high-value durable or wearable hardware with recurring reservoirs, pods, infusion sets and related consumables.

Automated systems are steadily becoming the technology benchmark for intensive insulin management. Competitive differentiation increasingly depends on algorithm design, CGM interoperability, pump size, wearability, training burden and ability to maintain automated control in everyday conditions.

Type 2 diabetes represents a major expansion opportunity. Historically, pump penetration among people with type 2 diabetes has been considerably lower than among type 1 patients. Systems designed to simplify dosing rather than increase device-management complexity could unlock a much larger insulin-using population.

Smart Blood Glucose Monitoring Systems

Connected blood glucose meters accounted for approximately 11.0% of the market, or USD 1.30 billion in 2025. This segment includes Bluetooth-enabled meters, connected testing systems, test strips and related digital monitoring hardware.

The category is mature and faces competitive pressure from CGM, particularly among insulin-treated patients. Nevertheless, it remains important because fingerstick testing retains a role in confirmation, lower-cost monitoring, episodic testing and patient populations where CGM is unavailable or unnecessary.

Future growth will depend less on standalone meter sales and more on integration. Meters connected to applications, virtual-care programs, clinician dashboards and payer-sponsored disease-management programs can retain strategic relevance despite slower hardware growth.

Smart Insulin Pens and Connected Pen Technologies

Smart insulin pens, connected pen caps and dose-tracking technologies represented an estimated 7.4% of the market, or approximately USD 0.88 billion in 2025.

These products address an important gap between traditional multiple daily injections and insulin pumps. Connected pen systems can digitally capture insulin doses and combine those data with CGM readings, helping clinicians understand whether poor glucose control reflects medication timing, insufficient dosing, missed injections or other factors.

This segment is well positioned among patients who prefer injections but want greater digital support. Adoption could accelerate if payers and health systems view connected pens as a lower-cost pathway to improve insulin management before escalating patients to pump therapy.

Digital Ketone and Multi-Parameter Diabetes Devices

Digitally connected ketone meters and multi-parameter monitoring systems represented approximately 4.8% of market value, or USD 0.57 billion in 2025. The segment is smaller but strategically relevant for patients at risk of diabetic ketoacidosis, intensive insulin users and specialty diabetes populations.

Growth will increasingly depend on integrating ketone and metabolic measurements into broader diabetes-management applications rather than offering isolated readings. Multi-analyte sensing remains an important longer-term innovation area, although broad clinical commercialization will depend on accuracy, regulatory evidence and practical value.

 

By Diabetes Type

Type 1 Diabetes

Type 1 diabetes represents the most technology-intensive patient segment and accounts for a disproportionately high share of digital diabetes device spending relative to its patient population. The United States has approximately 2.1 million people with diagnosed type 1 diabetes, including around 1.8 million adults and more than 300,000 children and adolescents.

CGM is increasingly central to type 1 diabetes management, while automated insulin delivery continues replacing traditional pump-only and multiple-injection workflows. Future value growth will come from AID upgrades, improved sensor performance, longer wear, greater system interoperability and pediatric adoption.

Insulin-Treated Type 2 Diabetes

Insulin-treated type 2 diabetes is expected to be the most important incremental growth population during 2026–2035. These patients have historically had lower penetration of CGM and automated delivery technology than people with type 1 diabetes, creating substantial headroom.

Medicare coverage expansion has been especially important for older insulin-treated patients. Manufacturers that simplify onboarding, reduce training requirements and integrate with primary care are likely to gain share because type 2 diabetes management is distributed across a much broader provider network than type 1 care.

Non-Insulin-Treated Type 2 Diabetes

Non-insulin-treated type 2 diabetes is emerging as a high-growth CGM opportunity. OTC glucose-monitoring systems reduce traditional access barriers, while growing interest in personalized response to diet, exercise and medication can support episodic or recurring sensor use.

The business model may differ from insulin-intensive diabetes because continuous year-round usage may not be necessary for every patient. Companies could develop periodic-use, subscription and treatment-response monitoring models that expand the addressable population without assuming permanent sensor wear.

Gestational Diabetes and Other Diabetes Populations

Gestational diabetes and other less common diabetes populations currently account for a comparatively small share of device revenue. However, pregnancy creates a clinically sensitive monitoring environment in which timely glucose information can have substantial value.

Device adoption depends heavily on labeling, clinician preference, payer policy and pregnancy-specific clinical evidence. The segment is unlikely to rival type 1 or type 2 diabetes in revenue but remains an important specialty opportunity.

 

By Technology Type

Bluetooth and Wireless-Connected Devices

Bluetooth and related wireless connectivity form the foundation of the modern digital diabetes ecosystem. Sensors, meters, pens and pumps increasingly transfer readings directly to smartphones or dedicated receivers.

The competitive issue is no longer whether a device is connected but whether the connection is dependable enough for medical use. Battery management, Bluetooth stability, application permissions and compatibility across smartphone operating systems can directly influence the user experience.

Cloud and App-Integrated Platforms

Cloud-enabled diabetes devices allow glucose and therapy data to move beyond the patient’s handset into clinician dashboards, caregiver interfaces and remote-management systems. This capability is increasingly important for pediatric care, elderly patients and virtual diabetes programs.

The market advantage of cloud integration increases as device manufacturers accumulate longitudinal data. Large datasets can improve product development and support clinical evidence, provided that companies maintain appropriate privacy, security and governance.

AI and Algorithm-Enabled Devices

Algorithm-enabled systems represent one of the fastest-growing technology groups. Automated insulin dosing is the most commercially mature use case, while predictive glucose alerts and pattern-recognition tools are increasingly embedded throughout digital diabetes platforms.

The value of algorithms will increasingly be judged by clinical outcomes and reduced patient burden rather than novelty. Systems that require extensive manual correction may have difficulty competing with platforms that provide effective automation while preserving appropriate safety controls.

Interoperable Automated Insulin Delivery Technology

Interoperability is transforming insulin delivery by enabling independently regulated components to operate together. Compatible pumps, CGMs and automated glycemic controllers can form integrated treatment systems.

This model can accelerate innovation because every product generation does not necessarily require a completely closed proprietary ecosystem. Manufacturers with highly desirable interoperable components can participate in several combinations and potentially expand their installed base.

Wearable and Implantable Sensor Platforms

Wearable glucose sensing dominates current adoption, but implantable technologies create an alternative for patients seeking significantly longer sensor duration. Wearables will maintain the largest volume because of convenience and non-invasive replacement, while implantable systems can serve differentiated patient needs.

Long-term competition will revolve around balancing sensor longevity, insertion burden, accuracy, calibration requirements, cost and user preference.

 

By End User

Homecare and Individual Patients

Homecare is the dominant end-use environment because diabetes management occurs continuously rather than only during medical appointments. CGMs, meters, pumps and smart pens are used primarily by patients during ordinary daily activities.

Consumer usability therefore directly influences commercial success. Simple setup, comfortable wear, discreet form factors, understandable alerts and reliable refill access can have as much impact on retention as individual technical specifications.

Hospitals and Endocrinology Clinics

Hospitals and endocrinology practices remain strategically important because they initiate advanced diabetes technologies, educate patients and manage complex cases. Specialist recommendations can strongly influence device selection, particularly for AID systems and difficult-to-control diabetes.

Endocrinology practices increasingly require efficient data-management tools because connected devices generate substantial volumes of information. Manufacturers that streamline data review can create value for clinicians as well as patients.

Primary Care and Integrated Delivery Networks

Primary care represents an increasingly important growth channel because most people with type 2 diabetes are not managed exclusively by endocrinologists. Expanding digital technology into this population requires workflows that are usable by primary-care physicians, nurses, pharmacists and diabetes educators.

Integrated delivery networks can also negotiate standardized device pathways and payer arrangements across large populations, giving enterprise contracts growing strategic importance.

Retail Pharmacy and DME Channels

Retail pharmacy and durable medical equipment suppliers are major distribution and access intermediaries. As diabetes devices become easier to dispense through pharmacy benefits, manufacturers can reduce administrative friction and improve refill continuity.

OTC CGM makes the retail channel still more important. Pharmacies can become a point of education, acquisition and recurring sensor purchase rather than simply a fulfillment location for prescribed products.

Virtual Diabetes Care, Employer and Payer Programs

Connected glucose meters and CGMs are increasingly incorporated into virtual care, employer and payer-sponsored diabetes programs. These models use device-generated data to support coaching, medication management and risk stratification.

For device manufacturers, partnerships with virtual-care organizations can provide access to large patient populations outside conventional specialist channels. Buyers in this segment typically prioritize engagement, measurable clinical improvement, data integration and total program economics.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Digital Diabetes Care Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance reflects a combination of diabetes prevalence, population size, Medicare exposure, commercial insurance coverage, specialist availability, retail-pharmacy infrastructure, health-system digitization and consumer acceptance of wearable technology.

The South is the largest regional market, while the West is projected to record the fastest growth through 2035. The Northeast remains one of the most sophisticated markets for specialist-driven diabetes technology, while the Midwest provides a large and stable patient base with significant opportunities for connected care outside major urban centers.

South

The South represented approximately USD 4.12 billion in 2025, equivalent to nearly 35% of the national market. The region is projected to reach approximately USD 10.95 billion by 2035, representing an estimated CAGR of about 10.27%.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Tennessee, Kentucky, Alabama, Mississippi, Arkansas, Louisiana and Oklahoma, along with the District of Columbia under the broader regional commercial framework.

The South combines a large population base with some of the country’s highest diabetes burden. CDC geographic analyses consistently show that diagnosed diabetes prevalence is particularly elevated across many Southeastern and rural Southern communities. Nonmetropolitan Southern counties have historically shown meaningfully higher diabetes prevalence than large metropolitan counties, increasing the need for monitoring solutions that can function outside specialist centers.

Texas is one of the most important state markets nationally. Its population scale, large diabetes population and major healthcare hubs in Houston, Dallas-Fort Worth, Austin and San Antonio support strong demand for CGM, pumps and connected glucose devices. East Texas has a particularly high diabetes burden, creating opportunities for technologies that can extend monitoring into areas with uneven access to endocrinology.

Florida is similarly important because of its large older population. Medicare coverage has therefore had a particularly strong commercial effect. CGM systems with easy pharmacy or DME access, simplified training and caregiver data sharing are well positioned in the state.

Georgia, North Carolina, Tennessee and Virginia represent attractive growth markets supported by expanding metropolitan populations and major integrated health systems. Academic centers in these states also contribute to adoption of automated insulin delivery and advanced sensor technology.

Mississippi, Alabama, Louisiana, Arkansas, Kentucky, Oklahoma and West Virginia carry substantial diabetes burden but also present greater challenges involving rural access, income disparities and specialist shortages. Digital devices can provide significant clinical value, but commercial success requires affordable access, simple onboarding and strong pharmacy or remote-care distribution.

The South offers the largest absolute expansion opportunity because manufacturers can address both sophisticated metropolitan markets and underserved high-burden populations. Successful strategies will differ considerably between major urban health systems and lower-density rural communities.

West

The West accounted for approximately USD 2.85 billion in 2025 and is expected to reach about USD 8.30 billion by 2035, representing the fastest regional CAGR at approximately 11.28%.

The regional market includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

The West has a comparatively lower diabetes prevalence than some Southern markets, but it benefits from strong digital-health adoption, major technology ecosystems, large commercially insured populations and a high concentration of medical-device and software innovation.

California is the dominant Western state and one of the largest digital diabetes markets nationally. The state combines substantial population scale with a sophisticated technology environment and major healthcare systems. Abbott Diabetes Care, Dexcom and numerous digital-health organizations maintain important commercial or innovation connections to California, reinforcing the state’s influence on product development and early adoption.

California also represents an important test market for consumer-oriented glucose sensing. Consumers familiar with wearable devices, mobile applications and personalized health data are more likely to understand the value proposition of OTC metabolic monitoring.

Arizona and Nevada are attractive because of population growth and increasing older-adult populations. Both states can support rapid growth in Medicare-funded CGM and insulin-management technology.

Washington and Oregon have digitally mature health systems and strong acceptance of virtual care. Integrated care models can facilitate enterprise adoption of connected monitoring, particularly where glucose data are incorporated directly into population-health programs.

Colorado and Utah have younger and relatively technology-oriented populations alongside strong integrated health systems. They are attractive for cloud-connected monitoring, wearable devices and hybrid virtual-care models.

New Mexico, Idaho, Montana, Wyoming and Alaska represent smaller individual markets but illustrate the role digital care can play across geographically dispersed populations. Remote access, pharmacy availability and telehealth integration become more important where specialist centers are distant.

Hawaii is also relatively small in absolute device revenue but presents unique chronic-disease management needs related to geographic separation across islands.

The West is expected to gain national market share because digital diabetes care increasingly resembles a technology platform business. Consumer-friendly sensing, cloud connectivity, interoperability and virtual-care integration align closely with provider and patient behavior in many Western markets.

Northeast

The Northeast represented approximately USD 2.54 billion in 2025 and is forecast to reach approximately USD 6.47 billion by 2035, corresponding to an estimated CAGR of 9.80%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, Vermont and New Hampshire.

The Northeast is characterized by high specialist density, sophisticated academic medical centers and strong commercial insurance coverage. These factors support high adoption of premium diabetes technology even though population growth is slower than in major Southern and Western states.

New York represents the largest market in the region. New York City and surrounding metropolitan areas support substantial endocrinology networks, pediatric diabetes centers and academic health systems. Connected devices are increasingly important for managing large and diverse patient populations.

Pennsylvania and New Jersey provide large patient pools with extensive hospital networks, retail pharmacy access and commercially insured populations. These states are attractive for both prescription CGM and advanced insulin delivery.

Massachusetts is disproportionately influential relative to population size because of its biotechnology, medical-device and academic clinical ecosystem. The state is particularly important for advanced diabetes research and automated insulin delivery development.

Connecticut and Rhode Island are mature markets with strong healthcare infrastructure and relatively concentrated populations, supporting specialist-led technology adoption.

Maine, Vermont and New Hampshire have smaller populations but comparatively greater need for remote monitoring as patients outside urban centers may travel substantial distances for specialty care.

The Northeast is unlikely to match the West’s growth rate because penetration is already relatively mature. However, premium system adoption, sophisticated clinical workflows and strong reimbursement will preserve its high value per eligible patient.

Midwest

The Midwest accounted for approximately USD 2.33 billion in 2025 and is forecast to reach approximately USD 5.95 billion by 2035, representing an estimated CAGR of 9.83%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

The Midwest has a broad mix of major academic centers, integrated health systems, mid-sized cities and extensive rural populations. This creates opportunities across both premium diabetes technology and lower-complexity connected monitoring.

Illinois is the largest commercial market in the region, driven by the Chicago metropolitan area and its concentration of hospitals, specialists and health plans.

Ohio and Michigan have large diabetes populations and significant health-system infrastructure. These states offer substantial opportunities for CGM expansion among insulin-treated type 2 patients and Medicare beneficiaries.

Minnesota is strategically important because of its established medical-device ecosystem and sophisticated healthcare delivery organizations. It is well positioned for advanced insulin delivery, clinical evaluation and connected-care adoption.

Indiana, Wisconsin and Missouri provide meaningful diabetes-device demand across metropolitan and community health systems. Indiana has a relatively high diabetes burden, supporting substantial clinical need.

Iowa, Kansas and Nebraska represent attractive markets for remote data sharing and connected monitoring because specialist access can be more limited outside major cities.

North Dakota and South Dakota are smaller markets in absolute terms, but the clinical value of digital diabetes care may be high where patients are geographically dispersed. Technologies that allow remote review of glucose trends can reduce dependence on frequent in-person specialist visits.

The Midwest is expected to remain a stable, durable market. Growth will depend heavily on increasing adoption among people with type 2 diabetes rather than relying primarily on penetration within already technology-intensive type 1 populations.

 

Key Market Players

The U.S. Digital Diabetes Care Devices competitive landscape is concentrated around a limited number of companies in CGM and automated insulin delivery, while blood glucose monitoring, digital insulin delivery and software-connected ecosystems remain more fragmented.

Abbott Diabetes Care and Dexcom are the central competitors in U.S. CGM. Their scale in disposable sensors, consumer awareness, pharmacy access and connected applications creates substantial competitive barriers. OTC glucose sensing introduces another layer of competition in which brand, pricing and consumer experience become increasingly important.

Insulet, Tandem Diabetes Care and Medtronic Diabetes are major competitors in connected and automated insulin delivery. Insulet’s tubeless architecture, Tandem’s automated pump ecosystem and Medtronic’s integrated diabetes portfolio represent different approaches to automation and user experience.

Senseonics is strategically differentiated through implantable CGM, while Beta Bionics and Sequel Med Tech contribute new competitive approaches to automated insulin delivery.

Other important participants include Roche Diabetes Care, LifeScan, Ascensia Diabetes Care, embecta, CeQur, DarioHealth, Teladoc Health/Livongo, Glooko, Welldoc, AgaMatrix, Trividia Health, One Drop, Tidepool, Modular Medical and Ypsomed.

The competitive hierarchy during 2026–2035 will be determined less by standalone hardware performance and more by ecosystem strength. Sensor accuracy will remain essential, but manufacturers must also compete on automated dosing, interoperability, pharmacy coverage, reimbursement support, digital user experience, data sharing, manufacturing reliability and recurring patient retention.

Scale will matter increasingly because sensor manufacturing and payer negotiation reward large installed bases. Nevertheless, smaller innovators can gain meaningful positions by solving specific workflow problems, particularly in simplified insulin delivery, longer-duration monitoring or interoperability.

 

Recent Developments

Recent U.S. developments demonstrate that digital diabetes technology is expanding simultaneously into more automated prescription care and broader consumer access.

In March 2024, the FDA cleared the Dexcom Stelo Glucose Biosensor System as the first OTC continuous glucose monitor in the United States for eligible adults not using insulin. The decision established a direct-access regulatory category for glucose sensing outside traditional prescription pathways and created a new competitive frontier for consumer-oriented metabolic monitoring.

In June 2024, Abbott’s Libre Rio CGM received FDA clearance for OTC non-intensive glucose management. This reinforced the transition toward a multi-player OTC market and increased competitive pressure around consumer pricing, retail access and sensor experience.

In July 2024, the FDA approved Medtronic’s Simplera continuous glucose monitoring system, adding another smartphone-connected sensor option to the U.S. technology landscape.

In August 2024, the FDA expanded the indication of Insulet’s SmartAdjust technology used in the Omnipod 5 system to adults with type 2 diabetes. The clearance was strategically significant because automated insulin dosing had historically been concentrated primarily within type 1 diabetes. The move materially strengthens the long-term addressable market for automated insulin delivery.

In September 2024, Senseonics received FDA clearance for its Eversense 365 CGM system. The development extended implantable glucose monitoring toward a one-year sensor-duration model, differentiating the platform from more frequently replaced wearable sensors.

During 2025, smartphone dependence became a more prominent safety consideration. The FDA issued a safety communication concerning the possibility that smartphone-compatible diabetes devices could fail to deliver critical alerts because of hardware settings, software configurations or operating-system changes. The issue highlights a broader reality for digital medical devices: consumer electronics infrastructure can become part of the clinical risk environment.

The competitive environment continued evolving in 2025 and 2026 as new insulin-delivery systems progressed through FDA pathways. Additional clearances involving the twiist automated insulin delivery system and Beta Bionics’ iLet ACE Pump increased competitive diversity within interoperable insulin delivery.

In June 2026, the FDA cleared a version of Dexcom’s Stelo system for OTC use in children aged two years and older who do not use insulin, extending OTC glucose-monitoring access beyond the initial adult-only indication.

The FDA also cleared the Dexcom G7 15 Day CGM in June 2026, demonstrating the continuing industry movement toward longer wear. Longer duration can reduce replacement frequency, potentially improve convenience and alter sensor economics.

These developments collectively show where competition is moving: broader eligibility, longer sensor wear, consumer access, type 2 diabetes automation, interoperability and reduced daily management burden.

 

Conclusion

The U.S. Digital Diabetes Care Devices Market Size & Share is positioned to expand from approximately USD 11.84 billion in 2025 to USD 31.67 billion by 2035, supported by a 10.34% CAGR during 2026–2035.

The market’s long-term strength is driven by a combination of exceptional disease burden, recurring consumable economics, expanding CGM eligibility, reimbursement improvement, automated insulin delivery, OTC monitoring, smartphone integration and the growing ability to convert raw glucose information into actionable treatment decisions.

Continuous glucose monitoring will remain the largest product category, but the highest strategic value will increasingly emerge from interconnected ecosystems combining sensing, algorithmic interpretation and drug delivery. Automated insulin delivery expansion into type 2 diabetes could materially alter the competitive structure because it opens a patient population many times larger than the historical pump market.

The device industry must nevertheless manage several execution risks. Reimbursement remains central to prescription-device penetration. Consumer willingness to pay will determine the scale of OTC monitoring. Data overload can limit clinical value if provider workflows are poorly designed. Smartphone dependence introduces new reliability considerations. Increasing competition can also create pricing pressure as CGM and pump categories mature.

Regionally, the South will remain the largest U.S. market, supported by population scale and high diabetes burden. The West is expected to grow fastest, supported by digital-health adoption and consumer acceptance of connected technology. The Northeast will retain high premium-device penetration, while the Midwest offers substantial opportunity for expansion among insulin-treated type 2 and geographically dispersed populations.

For manufacturers, investors, distributors, payers and healthcare providers evaluating this market, the central strategic question is no longer whether diabetes care will become more digital. That transition is already underway. The more important questions are which patient groups will be added next, which devices will become preferred platforms, how reimbursement will evolve, how rapidly automation reaches type 2 diabetes, and which manufacturers can sustain patient engagement over years of recurring device use.

The companies positioned to lead through 2035 will be those capable of combining clinically reliable sensing, intuitive patient experiences, automation, payer access, interoperable technology, strong manufacturing scale and evidence demonstrating that digital diabetes devices improve both patient outcomes and the economics of chronic care.

 

TABLE OF CONTENTS

1. U.S. Digital Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Digital Diabetes Care Device Manufacturers
1.6.2. Glucose Sensor, Semiconductor and Component Suppliers
1.6.3. Insulin Delivery and Pump Technology Manufacturers
1.6.4. Hospitals, Endocrinology Clinics and Integrated Delivery Networks
1.6.5. Primary Care and Diabetes Management Providers
1.6.6. Retail Pharmacies, DME Suppliers and Distribution Partners
1.6.7. Commercial Payers, PBMs, Medicare and Medicaid Stakeholders
1.6.8. Virtual Diabetes Care and Remote Patient Monitoring Providers
1.6.9. FDA, CMS and Clinical Decision-Makers

What this section provides: This section defines the U.S. digital diabetes care devices market boundary, study scope, methodology, assumptions and stakeholder ecosystem, helping clients understand how connected glucose monitoring and digital insulin-delivery technologies are measured and validated.

2. U.S. Digital Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2025 – USD 11.84 Billion
2.8. Market Size Forecast, 2035 – USD 31.67 Billion
2.9. Forecast CAGR, 2026–2035 – 10.34%
2.10. High-Growth Opportunity Areas
2.11. Leading Product and Technology Opportunities
2.12. Key Regional and State-Level Opportunity Hotspots

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, major demand pools, technology shifts, competitive intensity and priority investment opportunities across the U.S. digital diabetes care devices industry.

3. U.S. Digital Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes and Prediabetes Burden
3.1.2. Accelerating Continuous Glucose Monitoring Adoption
3.1.3. Expansion of CGM Beyond Intensive Insulin Users
3.1.4. Growth of Automated Insulin Delivery Systems
3.1.5. Medicare and Commercial Payer Coverage Expansion
3.1.6. Increasing Adoption of Connected Home Diabetes Management
3.1.7. Growth of OTC Continuous Glucose Monitoring
3.1.8. Increasing Smartphone and Wearable Health Technology Adoption
3.1.9. Rising Demand for Personalized and Data-Driven Diabetes Management

3.2. Restraints and Their Impact Analysis
3.2.1. High Recurring Sensor and Consumable Costs
3.2.2. Insurance Coverage and Prior Authorization Complexity
3.2.3. Digital Literacy and Patient Training Barriers
3.2.4. Device Connectivity and Smartphone Compatibility Issues
3.2.5. Data Privacy and Cybersecurity Concerns
3.2.6. Device Discontinuation and Patient Adherence Challenges

3.3. Opportunities and Their Impact Analysis
3.3.1. CGM Expansion in Non-Insulin-Treated Type 2 Diabetes
3.3.2. Automated Insulin Delivery Expansion in Type 2 Diabetes
3.3.3. OTC and Direct-to-Consumer Glucose Monitoring
3.3.4. Smart Insulin Pen and Connected Injection Management
3.3.5. Longer-Wear and Implantable Glucose Sensors
3.3.6. Virtual Diabetes Care and Remote Patient Monitoring
3.3.7. AI-Assisted Glucose Pattern Recognition and Predictive Analytics
3.3.8. Pharmacy-Based Digital Diabetes Care Models

3.4. Challenges and Their Impact Analysis
3.4.1. Device Affordability and Health Equity
3.4.2. Sensor Accuracy and Reliability Expectations
3.4.3. Alarm Fatigue and Data Overload
3.4.4. Interoperability Across Diabetes Device Ecosystems
3.4.5. Reimbursement Variation Across Patient Populations
3.4.6. Technology Adoption Across Rural and Underserved Populations

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Digital Diabetes Clinical Workflow Economics Analysis
3.7. Payer, Pharmacy and DME Procurement Behavior Analysis
3.8. Patient Acquisition, Retention and Recurring Consumable Economics

What this section provides: This section explains the clinical, economic, reimbursement, behavioral and technology forces shaping U.S. digital diabetes device demand, enabling clients to evaluate both growth opportunities and commercial execution risks.

4. U.S. Digital Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Digitalization and Connected Diabetes Care Impact Analysis
4.6. Diabetes Device Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Continuous Glucose Monitoring Regulatory Landscape
4.7.2. Automated Insulin Delivery Regulatory Landscape
4.7.3. Interoperable Diabetes Device Regulatory Framework
4.7.4. OTC Glucose Monitoring Regulatory Landscape
4.7.5. Software and Mobile Application Safety Requirements

4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare CGM Coverage
4.8.2. Insulin Pump and AID Coverage
4.8.3. Durable Medical Equipment Coverage Pathways
4.8.4. Pharmacy Benefit Coverage Dynamics
4.8.5. Remote Patient Monitoring Reimbursement

4.9. Commercial Payer and PBM Formulary Landscape
4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Diabetes Initiatives and Public Health Programs
4.12. Impact of Escalating Geopolitical and Semiconductor Supply Risks
4.13. Cybersecurity, Data Privacy and Connected Device Risk Analysis
4.14. Payer and Health System Technology Evaluation Framework

What this section provides: This section gives clients a comprehensive view of regulation, reimbursement, pricing, payer access, supply chain, digital connectivity, technology adoption and external forces influencing the U.S. digital diabetes care devices market.

5. U.S. Digital Diabetes Care Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Continuous Glucose Monitoring Systems
5.1.2.1. Real-Time Continuous Glucose Monitoring Systems
5.1.2.2. Intermittently Scanned Glucose Monitoring Systems
5.1.2.3. OTC Continuous Glucose Monitoring Systems
5.1.2.4. Implantable Continuous Glucose Monitoring Systems
5.1.2.5. CGM Sensors
5.1.2.6. CGM Transmitters and Receivers

5.1.3. Connected and Automated Insulin Delivery Devices
5.1.3.1. Traditional Connected Insulin Pumps
5.1.3.2. Tubeless and Patch Insulin Pumps
5.1.3.3. Automated Insulin Delivery Systems
5.1.3.4. Insulin Pump Infusion Sets
5.1.3.5. Pump Reservoirs, Pods and Consumables

5.1.4. Smart Blood Glucose Monitoring Systems
5.1.4.1. Bluetooth-Enabled Blood Glucose Meters
5.1.4.2. Connected Test Strips and Accessories
5.1.4.3. App-Integrated Blood Glucose Monitoring Systems

5.1.5. Smart Insulin Pens and Connected Pen Technologies
5.1.5.1. Smart Reusable Insulin Pens
5.1.5.2. Connected Insulin Pen Caps and Attachments
5.1.5.3. Digital Dose-Tracking Systems

5.1.6. Digital Ketone and Multi-Parameter Diabetes Monitoring Devices
5.1.6.1. Connected Blood Ketone Meters
5.1.6.2. Combined Glucose and Ketone Monitoring Systems
5.1.6.3. Emerging Multi-Analyte Metabolic Sensors

What this section provides: This section identifies the digital diabetes device categories expected to contribute the largest revenue share and strongest growth through 2035, including CGM, automated insulin delivery, connected meters, smart pens and emerging sensing technologies.

6. U.S. Digital Diabetes Care Devices Market – By Diabetes Type

6.1. Overview
6.1.1. Segment Share Analysis, By Diabetes Type, 2025 & 2035 (%)
6.1.2. Type 1 Diabetes
6.1.2.1. Adult Type 1 Diabetes
6.1.2.2. Pediatric and Adolescent Type 1 Diabetes

6.1.3. Insulin-Treated Type 2 Diabetes
6.1.3.1. Multiple Daily Injection Users
6.1.3.2. Basal Insulin Users
6.1.3.3. Pump and Automated Insulin Delivery Users

6.1.4. Non-Insulin-Treated Type 2 Diabetes
6.1.4.1. Prescription CGM Users
6.1.4.2. OTC CGM Users
6.1.4.3. Intermittent and Episodic Glucose Monitoring Users

6.1.5. Gestational Diabetes
6.1.6. Other Diabetes and High-Risk Metabolic Populations

What this section provides: This section evaluates digital device demand by diabetes population, showing where CGM, connected insulin delivery and glucose-monitoring adoption are expected to expand most rapidly through 2035.

7. U.S. Digital Diabetes Care Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Individual Patients and Homecare Users
7.1.3. Hospitals and Health Systems
7.1.4. Endocrinology and Diabetes Specialty Clinics
7.1.5. Primary Care Practices and Integrated Delivery Networks
7.1.6. Pediatric Diabetes Centers
7.1.7. Virtual Diabetes Care and Remote Patient Monitoring Providers
7.1.8. Employer and Payer-Sponsored Diabetes Management Programs

What this section provides: This section explains which patient groups, care settings and healthcare organizations are expected to drive digital diabetes device initiation, recurring utilization and long-term technology adoption.

8. U.S. Digital Diabetes Care Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Bluetooth and Wireless-Connected Devices
8.1.3. Cloud and Mobile App-Integrated Platforms
8.1.4. AI and Algorithm-Enabled Diabetes Devices
8.1.5. Interoperable Automated Insulin Delivery Technologies
8.1.6. Wearable Sensor Technologies
8.1.7. Implantable Sensor Technologies
8.1.8. Predictive Glucose Analytics and Decision-Support Technologies

What this section provides: This section evaluates the enabling technologies transforming digital diabetes management, including wireless connectivity, cloud infrastructure, artificial intelligence, automated dosing, interoperability and next-generation sensing.

9. U.S. Digital Diabetes Care Devices Market – By Distribution & Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Distribution & Procurement Channel, 2025 & 2035 (%)
9.1.2. Retail Pharmacy Channel
9.1.3. Durable Medical Equipment Suppliers
9.1.4. Direct Manufacturer and Direct-to-Consumer Channels
9.1.5. Health Plan, PBM and Formulary-Based Channels
9.1.6. Hospital and Health System Enterprise Contracts
9.1.7. Endocrinology and Specialty Diabetes Supply Channels
9.1.8. Virtual Care, Employer and Population Health Contracts

What this section provides: This section helps clients understand how digital diabetes devices reach U.S. patients through pharmacy benefits, DME channels, direct distribution, payer formularies, institutional contracts and emerging direct-to-consumer models.

10. U.S. Digital Diabetes Care Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diabetes Prevalence and Addressable Patient Analysis
10.1.4. Regional CGM and Insulin Delivery Adoption Analysis
10.1.5. Regional Medicare, Commercial Payer and Pharmacy Access Dynamics
10.1.6. Regional Digital Health and Remote Care Adoption Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Digital Diabetes Device Manufacturers and Market Access Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Digital Diabetes Device Manufacturers and Market Access Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Digital Diabetes Device Manufacturers and Market Access Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Digital Diabetes Device Manufacturers and Market Access Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Distribution & Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 U.S. states, helping clients identify diabetes-burden hotspots, CGM and automated insulin delivery adoption opportunities, payer-access differences, digital-health penetration and priority commercial geographies.

11. U.S. Digital Diabetes Care Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players

11.3. Company Profiles

11.3.1. Abbott Diabetes Care
11.3.2. Dexcom, Inc.
11.3.3. Medtronic Diabetes
11.3.4. Insulet Corporation
11.3.5. Tandem Diabetes Care, Inc.
11.3.6. Senseonics Holdings, Inc.
11.3.7. Roche Diabetes Care
11.3.8. LifeScan, Inc.
11.3.9. Ascensia Diabetes Care
11.3.10. embecta Corp.
11.3.11. Beta Bionics, Inc.
11.3.12. Sequel Med Tech, LLC
11.3.13. CeQur Corporation
11.3.14. DarioHealth Corp.
11.3.15. Teladoc Health / Livongo
11.3.16. Glooko, Inc.
11.3.17. Welldoc, Inc.
11.3.18. AgaMatrix, Inc.
11.3.19. Trividia Health, Inc.
11.3.20. Tidepool
11.3.21. Modular Medical, Inc.
11.3.22. Ypsomed
11.3.23. Nemaura Medical Inc.
11.3.24. Bigfoot Biomedical / Abbott
11.3.25. Companion Medical / Medtronic

11.4. Competitive Benchmarking by Product Portfolio
11.5. Competitive Benchmarking by CGM Installed Base
11.6. Competitive Benchmarking by Automated Insulin Delivery Capabilities
11.7. Competitive Benchmarking by Distribution and Reimbursement Access
11.8. Strategic Partnerships, Licensing and Interoperability Agreements
11.9. Mergers, Acquisitions and Portfolio Consolidation

Company Profile Coverage: Each company profile will include company overview, U.S. digital diabetes device portfolio, market positioning, technology strategy, financial positioning where available, clinical pipeline, FDA regulatory developments, reimbursement strategy, partnerships, interoperability initiatives and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, CGM and insulin-delivery ecosystem intelligence, innovation direction and strategic assessment of approximately 20–25 major and emerging companies.

12. U.S. Digital Diabetes Care Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. OTC Continuous Glucose Monitoring
12.2.2. Longer-Wear and Implantable CGM
12.2.3. Automated Insulin Delivery for Type 2 Diabetes
12.2.4. AI-Assisted Insulin Dosing and Predictive Analytics
12.2.5. Interoperable Diabetes Device Ecosystems
12.2.6. Smart Insulin Pens and Connected Injection Management
12.2.7. Multi-Analyte Metabolic Sensors
12.2.8. Non-Invasive Glucose Monitoring Technologies
12.2.9. Smartphone-Controlled Diabetes Devices
12.2.10. Virtual Diabetes Care and Remote Patient Monitoring

12.3. Emerging Business Trends
12.3.1. Shift from Prescription-Only to Consumer-Accessible Monitoring
12.3.2. Sensor Subscription and Recurring Revenue Models
12.3.3. Pharmacy-Centric Diabetes Device Distribution
12.3.4. Device-Software-Payer Ecosystem Integration
12.3.5. Value-Based Diabetes Technology Contracts

12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Patient Population Expansion Opportunity Analysis
12.7. Technology Adoption Curve, 2026–2035
12.8. Market White-Space Analysis

What this section provides: This section prepares clients for future technology shifts, patient-pool expansion, changes in reimbursement and distribution, evolving competitive structures and investment opportunities through 2035.

13. U.S. Digital Diabetes Care Devices Market: Strategic Recommendations

13.1. Recommendations for Digital Diabetes Device Manufacturers
13.2. Recommendations for CGM Manufacturers
13.3. Recommendations for Insulin Pump and Automated Delivery Companies
13.4. Recommendations for Hospitals and Health Systems
13.5. Recommendations for Endocrinology and Primary Care Providers
13.6. Recommendations for Commercial Payers, PBMs and Medicare-Focused Stakeholders
13.7. Recommendations for Retail Pharmacies and DME Suppliers
13.8. Recommendations for Investors and Private Equity Firms
13.9. Recommendations for Distributors and Channel Partners
13.10. Recommendations for New Entrants and Startups
13.11. Go-to-Market Strategy Considerations
13.12. Product Positioning and Portfolio Expansion Guidance
13.13. Reimbursement and Market Access Strategy
13.14. State-Level Commercial Prioritization Strategy
13.15. Partnership and Interoperability Strategy

What this section provides: This section converts market intelligence into actionable strategies for market entry, product positioning, payer access, channel expansion, state prioritization, investment planning, portfolio development and competitive differentiation.

14. U.S. Digital Diabetes Care Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Market Estimate and Modeling Disclaimer
14.7. Regulatory and Reimbursement Information Disclaimer

What this section provides: This section clarifies the report’s scope limitations, legal boundaries, data-use terms, forecasting assumptions, market-modeling methodology and limitations relating to regulatory, reimbursement and third-party information.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Digital Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Digital Diabetes Care Devices Market: Research Methodology Framework
TABLE 4: U.S. Digital Diabetes Care Devices Market: Key Assumptions
TABLE 5: U.S. Digital Diabetes Care Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Digital Diabetes Care Devices Market: Stakeholder Analysis
TABLE 7: U.S. Digital Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Digital Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Digital Diabetes Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. Digital Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Digital Diabetes Care Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Digital Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Digital Diabetes Care Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Digital Diabetes Care Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Digital Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Digital Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Digital Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Digital Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Digital Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Digital Diabetes Care Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Digital Diabetes Care Devices Market: Payer, Pharmacy and DME Procurement Behavior Matrix
TABLE 22: U.S. Digital Diabetes Care Devices Market: Patient Acquisition, Retention and Recurring Consumable Economics
TABLE 23: U.S. Digital Diabetes Care Devices Market: PESTEL Analysis
TABLE 24: U.S. Digital Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Digital Diabetes Care Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Digital Diabetes Care Devices Market: Value Chain Analysis
TABLE 27: U.S. Digital Diabetes Care Devices Market: Supply Chain Analysis
TABLE 28: U.S. Digital Diabetes Care Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 29: U.S. Digital Diabetes Care Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Digital Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Digital Diabetes Care Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Digital Diabetes Care Devices Market: Commercial Payer and PBM Formulary Landscape
TABLE 33: U.S. Digital Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. Digital Diabetes Care Devices Market: Government Diabetes Initiatives and Public Health Programs
TABLE 35: U.S. Digital Diabetes Care Devices Market: Geopolitical, Semiconductor and Component Supply Risk
TABLE 36: U.S. Digital Diabetes Care Devices Market: Cybersecurity and Data Privacy Risk Analysis
TABLE 37: U.S. Digital Diabetes Care Devices Market: Payer and Health System Technology Evaluation Framework
TABLE 38: U.S. Digital Diabetes Care Devices Market: Product Type Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product Type
TABLE 40: U.S. Digital Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 41: U.S. Digital Diabetes Care Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 42: Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Connected and Automated Insulin Delivery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Smart Blood Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Smart Insulin Pens and Connected Pen Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Digital Ketone and Multi-Parameter Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Digital Diabetes Care Devices Market: Diabetes Type Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Diabetes Type
TABLE 49: U.S. Digital Diabetes Care Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 50: U.S. Digital Diabetes Care Devices Market: Segment Share Analysis, by Diabetes Type, 2025 & 2035 (%)
TABLE 51: Type 1 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Non-Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Gestational Diabetes and Other Diabetes Populations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Digital Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by End User
TABLE 57: U.S. Digital Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 58: U.S. Digital Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 59: Individual Patients and Homecare Users Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Endocrinology and Diabetes Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Primary Care Practices and Integrated Delivery Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Pediatric Diabetes Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Virtual Diabetes Care and Remote Patient Monitoring Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Employer and Payer-Sponsored Diabetes Management Programs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Digital Diabetes Care Devices Market: Technology Type Snapshot, 2025
TABLE 67: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 68: U.S. Digital Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 69: U.S. Digital Diabetes Care Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 70: Bluetooth and Wireless-Connected Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Cloud and Mobile App-Integrated Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: AI and Algorithm-Enabled Diabetes Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: Interoperable Automated Insulin Delivery Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: Wearable Sensor Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Implantable Sensor Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: Predictive Glucose Analytics and Decision-Support Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Digital Diabetes Care Devices Market: Distribution & Procurement Channel Snapshot, 2025
TABLE 78: Segment Dashboard; Definition and Scope, by Distribution & Procurement Channel
TABLE 79: U.S. Digital Diabetes Care Devices Market, by Distribution & Procurement Channel, 2021–2035 (US$ Billion)
TABLE 80: U.S. Digital Diabetes Care Devices Market: Segment Share Analysis, by Distribution & Procurement Channel, 2025 & 2035 (%)
TABLE 81: Retail Pharmacy Channel Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: Durable Medical Equipment Suppliers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: Direct Manufacturer and Direct-to-Consumer Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: Health Plan, PBM and Formulary-Based Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: Hospital and Health System Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: Endocrinology and Specialty Diabetes Supply Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: Virtual Care, Employer and Population Health Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. Digital Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 89: Segment Dashboard; Definition and Scope, by Geography
TABLE 90: U.S. Digital Diabetes Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 91: U.S. Digital Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 92: U.S. Digital Diabetes Care Devices Market: Regional Diabetes Prevalence and Addressable Patient Analysis
TABLE 93: U.S. Digital Diabetes Care Devices Market: Regional CGM and Insulin Delivery Adoption Analysis
TABLE 94: U.S. Digital Diabetes Care Devices Market: Regional Medicare, Commercial Payer and Pharmacy Access Dynamics
TABLE 95: West Region U.S. Digital Diabetes Care Devices Market: Regional Overview and Trends
TABLE 96: West Region U.S. Digital Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 97: West Region U.S. Digital Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. Digital Diabetes Care Devices Market: Segment Analysis, 2021–2035 (US$ Billion)
TABLE 99: California Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Washington Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Arizona Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Colorado Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Oregon Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Utah Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Nevada Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: New Mexico Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Idaho Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Montana Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Wyoming Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Alaska Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Hawaii Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Digital Diabetes Care Devices Market: Regional Overview and Trends
TABLE 113: Northeast Region U.S. Digital Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 114: Northeast Region U.S. Digital Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Digital Diabetes Care Devices Market: Segment Analysis, 2021–2035 (US$ Billion)
TABLE 116: New York Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Massachusetts Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: New Jersey Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Pennsylvania Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Connecticut Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Maine Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Vermont Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Hampshire Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Rhode Island Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Delaware Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Digital Diabetes Care Devices Market: Regional Overview and Trends
TABLE 127: South Region U.S. Digital Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 128: South Region U.S. Digital Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Digital Diabetes Care Devices Market: Segment Analysis, 2021–2035 (US$ Billion)
TABLE 130: Texas Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Florida Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Georgia Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: North Carolina Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Tennessee Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: South Carolina Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Alabama Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Mississippi Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Louisiana Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Arkansas Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Kentucky Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Oklahoma Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Virginia Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Maryland Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: West Virginia Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Midwest Region U.S. Digital Diabetes Care Devices Market: Regional Overview and Trends
TABLE 146: Midwest Region U.S. Digital Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 147: Midwest Region U.S. Digital Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. Digital Diabetes Care Devices Market: Segment Analysis, 2021–2035 (US$ Billion)
TABLE 149: Illinois Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Ohio Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Michigan Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Minnesota Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Indiana Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Wisconsin Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Missouri Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Iowa Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Kansas Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Nebraska Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: North Dakota Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: South Dakota Digital Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: U.S. Digital Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 162: U.S. Digital Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 163: U.S. Digital Diabetes Care Devices Market: Company Positioning Matrix
TABLE 164: U.S. Digital Diabetes Care Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 165: U.S. Digital Diabetes Care Devices Market: CGM Installed Base and Sensor Portfolio Benchmarking
TABLE 166: U.S. Digital Diabetes Care Devices Market: Automated Insulin Delivery Capability Benchmarking
TABLE 167: U.S. Digital Diabetes Care Devices Market: Distribution, Reimbursement and Market Access Benchmarking
TABLE 168: U.S. Digital Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 169: Abbott Diabetes Care: Company Profile
TABLE 170: Dexcom, Inc.: Company Profile
TABLE 171: Medtronic Diabetes: Company Profile
TABLE 172: Insulet Corporation: Company Profile
TABLE 173: Tandem Diabetes Care, Inc.: Company Profile
TABLE 174: Senseonics Holdings, Inc.: Company Profile
TABLE 175: Roche Diabetes Care: Company Profile
TABLE 176: LifeScan, Inc.: Company Profile
TABLE 177: Ascensia Diabetes Care: Company Profile
TABLE 178: embecta Corp.: Company Profile
TABLE 179: Beta Bionics, Inc.: Company Profile
TABLE 180: Sequel Med Tech, LLC: Company Profile
TABLE 181: CeQur Corporation: Company Profile
TABLE 182: DarioHealth Corp.: Company Profile
TABLE 183: Teladoc Health / Livongo: Company Profile
TABLE 184: Glooko, Inc.: Company Profile
TABLE 185: Welldoc, Inc.: Company Profile
TABLE 186: AgaMatrix, Inc.: Company Profile
TABLE 187: Trividia Health, Inc.: Company Profile
TABLE 188: Tidepool: Company Profile
TABLE 189: Modular Medical, Inc.: Company Profile
TABLE 190: Ypsomed: Company Profile
TABLE 191: Nemaura Medical Inc.: Company Profile
TABLE 192: Bigfoot Biomedical / Abbott: Company Profile
TABLE 193: Companion Medical / Medtronic: Company Profile
TABLE 194: U.S. Digital Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 195: U.S. Digital Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 196: U.S. Digital Diabetes Care Devices Market: Emerging Business Trends
TABLE 197: U.S. Digital Diabetes Care Devices Market: OTC CGM Opportunity Analysis
TABLE 198: U.S. Digital Diabetes Care Devices Market: Type 2 Diabetes AID Expansion Opportunity
TABLE 199: U.S. Digital Diabetes Care Devices Market: Patient Population Expansion Opportunity Analysis
TABLE 200: U.S. Digital Diabetes Care Devices Market: Technology Adoption Curve, 2026–2035
TABLE 201: U.S. Digital Diabetes Care Devices Market: Investment Prioritization and White-Space Matrix
TABLE 202: U.S. Digital Diabetes Care Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 203: U.S. Digital Diabetes Care Devices Market: Strategic Recommendations for CGM and AID Companies
TABLE 204: U.S. Digital Diabetes Care Devices Market: Strategic Recommendations for Healthcare Providers
TABLE 205: U.S. Digital Diabetes Care Devices Market: Strategic Recommendations for Payers, PBMs and Channel Partners
TABLE 206: U.S. Digital Diabetes Care Devices Market: Strategic Recommendations for Investors and New Entrants
TABLE 207: U.S. Digital Diabetes Care Devices Market: Go-to-Market Strategy Considerations
TABLE 208: U.S. Digital Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 209: U.S. Digital Diabetes Care Devices Market: Reimbursement, State Prioritization and Partnership Strategy
TABLE 210: U.S. Digital Diabetes Care Devices Market: Scope Limitation
TABLE 211: U.S. Digital Diabetes Care Devices Market: Data Use Limitation
TABLE 212: U.S. Digital Diabetes Care Devices Market: Forecasting Limitation
TABLE 213: U.S. Digital Diabetes Care Devices Market: Legal Disclaimer
TABLE 214: U.S. Digital Diabetes Care Devices Market: Third-Party Data Disclaimer
TABLE 215: U.S. Digital Diabetes Care Devices Market: Market Estimate and Modeling Disclaimer
TABLE 216: U.S. Digital Diabetes Care Devices Market: Regulatory and Reimbursement Information Disclaimer

List of Figures

FIGURE 1: U.S. Digital Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Digital Diabetes Care Market Ecosystem
FIGURE 4: Stakeholder Ecosystem and Commercial Flow
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Digital Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Digital Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: U.S. Digital Diabetes Care Devices Market Dynamics
FIGURE 10: Drivers, Restraints, Opportunities and Challenges Impact Matrix
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Digital Diabetes Clinical Workflow Economics Framework
FIGURE 13: Payer, Pharmacy and DME Market Access Decision Framework
FIGURE 14: PESTEL Analysis
FIGURE 15: Porter’s Five Forces Analysis
FIGURE 16: Value Chain Analysis
FIGURE 17: Supply Chain Analysis
FIGURE 18: FDA Regulatory and CMS Reimbursement Framework
FIGURE 19: Digitalization and Connected Diabetes Innovation Landscape
FIGURE 20: Cybersecurity, Smartphone Connectivity and Data Privacy Risk Framework
FIGURE 21: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 22: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Connected and Automated Insulin Delivery Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Smart Blood Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Smart Insulin Pens and Connected Pen Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Digital Ketone and Multi-Parameter Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Diabetes Type Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Diabetes Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Type 1 Diabetes Digital Device Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Insulin-Treated Type 2 Diabetes Digital Device Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Non-Insulin-Treated Type 2 Diabetes Digital Device Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Gestational and Other Diabetes Populations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 35: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Individual Patients and Homecare Users Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hospitals and Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Endocrinology and Diabetes Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Primary Care and Integrated Delivery Networks Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Pediatric Diabetes Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Virtual Diabetes Care and Remote Patient Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Employer and Payer-Sponsored Diabetes Management Programs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Bluetooth and Wireless-Connected Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Cloud and Mobile App-Integrated Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: AI and Algorithm-Enabled Diabetes Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Interoperable Automated Insulin Delivery Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Wearable Sensor Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Implantable Sensor Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Predictive Glucose Analytics and Decision-Support Technologies Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 52: Distribution & Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Distribution & Procurement Channel Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Retail Pharmacy Channel Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Durable Medical Equipment Suppliers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Direct Manufacturer and Direct-to-Consumer Channels Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 57: Health Plan, PBM and Formulary-Based Channels Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 58: Hospital and Health System Enterprise Contracts Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 59: Endocrinology and Specialty Diabetes Supply Channels Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 60: Virtual Care, Employer and Population Health Contracts Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 61: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 62: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: West Region U.S. Digital Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 64: West Region Market Share Analysis by State, 2025
FIGURE 65: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: California Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Washington Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Arizona Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Colorado Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Oregon Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Utah Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Nevada Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Mexico Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Idaho Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Montana Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Wyoming Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Alaska Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Hawaii Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Northeast Region U.S. Digital Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 80: Northeast Region Market Share Analysis by State, 2025
FIGURE 81: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: New York Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Massachusetts Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: New Jersey Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Pennsylvania Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Connecticut Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Maine Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Vermont Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: New Hampshire Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Rhode Island Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Delaware Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: South Region U.S. Digital Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 93: South Region Market Share Analysis by State, 2025
FIGURE 94: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Texas Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Florida Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Georgia Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: North Carolina Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Tennessee Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: South Carolina Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Alabama Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Mississippi Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Louisiana Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Arkansas Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Kentucky Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Oklahoma Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Virginia Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Maryland Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: West Virginia Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Midwest Region U.S. Digital Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 111: Midwest Region Market Share Analysis by State, 2025
FIGURE 112: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Illinois Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Ohio Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Michigan Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Minnesota Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Indiana Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Wisconsin Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Missouri Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Iowa Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Kansas Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Nebraska Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: North Dakota Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: South Dakota Digital Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 125: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 126: Company Positioning Matrix
FIGURE 127: Key Player Product Portfolio Benchmarking
FIGURE 128: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 129: CGM and Automated Insulin Delivery Competitive Ecosystem Map
FIGURE 130: Future Market Scenario Analysis, 2026–2035
FIGURE 131: Disruptive Technologies Impact Matrix
FIGURE 132: Digital Diabetes Device Innovation Roadmap
FIGURE 133: OTC Continuous Glucose Monitoring Adoption Roadmap
FIGURE 134: Type 2 Diabetes Automated Insulin Delivery Opportunity Map
FIGURE 135: Emerging Business Trends Matrix
FIGURE 136: Investment Prioritization Matrix
FIGURE 137: Digital Diabetes Technology Adoption Curve, 2026–2035
FIGURE 138: Market White-Space and Patient Expansion Opportunity Map
FIGURE 139: Strategic Growth Roadmap for U.S. Digital Diabetes Device Companies
FIGURE 140: Go-to-Market Strategy Framework
FIGURE 141: Product Positioning and Portfolio Expansion Framework
FIGURE 142: Reimbursement and Market Access Strategy Framework
FIGURE 143: State-Level Commercial Prioritization Framework
FIGURE 144: Partnership and Interoperability Strategy Framework
FIGURE 145: Report Scope and Disclaimer Framework